UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed	by the R	Registrant 🗵	Filed by a party other than the Registrant $\ \Box$					
Check	the app	propriate box:						
	Prelin	ninary Proxy Stateme	ent					
	Confi	dential, for Use of t	he Commission Only (as permitted by Rule 14a-6(e)(2))					
	Defini	itive Proxy Statemen	t					
\boxtimes	Defini	itive Additional Mate	erials					
	Solici	ting Material Pursuar	nt to §240.14a-12					
			Cerevel Therapeutics Holdings, Inc. (Name of Registrant as Specified In Its Charter)					
			(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)					
Paym	ent of F	iling Fee (Check the	appropriate box):					
\boxtimes	No fe	e required.						
	Fee co	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.						
	(1)	Title of each class of	of securities to which transaction applies:					
	(2)	Aggregate number	of securities to which transaction applies:					
	(3)		her underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the ted and state how it was determined):					
	(4)	Proposed maximum	n aggregate value of transaction:					
	(5)	Total fee paid:						
	Fee pa	aid previously with p	reliminary materials.					
			ne fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was ne previous filing by registration statement number, or the Form or Schedule and the date of its filing.					
	(1)	Amount Previously	⁷ Paid:					
	(2)	Form, Schedule or	Registration Statement No.:					



Cerevel Therapeutics Holdings, Inc. Important Notice Regarding the **Availability of Proxy Materials**

Annual Meeting of Stockholders to be held on June 10, 2021

For stockholders of record on April 12, 2021

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/CERE

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/CERE

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.



If you want to receive a paper or email copy of the proxy materials, you must request one. There is no charge to you must make this request on or before May 31, 2021.

To order paper materials, use one of the following methods.



INTERNET www.investorelections.com/CERE

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.





If requesting material by email, please send email with the 12 digit control number (located in the subject line. No other requests, instruct other inquiries should be included with your er requesting material.

Cerevel Therapeutics Holdings, Inc.

Meeting Type: Annual Meeting of Stockholders

Date: Thursday, June 10, 2021 Time: 09:00 AM. Eastern Time

Annual Meeting to be held virtually via the Internet please visit www.proxydocs.com/CERE for more details

You must register to attend the meeting online and/or participate at www.proxydocs.com/CERE

SEE REVERSE FOR FULL AGENDA

Cerevel Therapeutics Holdings, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR PROPOSALS 1 AND 2

PROPOSAL

- Election of three Class I director nominees.
 1.01 N. Anthony Coles

 - 1.02 Morris Birnbaum
 - 1.03 Christopher Gordon
- 2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm.